Vertex Pharmaceuticals
VRTX
964 hedge funds and large institutions have $70.6B invested in Vertex Pharmaceuticals in 2020 Q2 according to their latest regulatory filings, with 174 funds opening new positions, 405 increasing their positions, 271 reducing their positions, and 59 closing their positions.
195% more first-time investments, than exits
New positions opened: 174 | Existing positions closed: 59
49% more repeat investments, than reductions
Existing positions increased: 405 | Existing positions reduced: 271
21% more capital invested
Capital invested by funds: $58.4B → $70.6B (+$12.2B)
13% more funds holding
Funds holding: 856 → 964 (+108)
1% more call options, than puts
Call options by funds: $326M | Put options by funds: $324M
0.83% less ownership
Funds ownership: 94.74% → 93.91% (-0.83%)
16% less funds holding in top 10
Funds holding in top 10: 32 → 27 (-5)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$863M |
| 2 |
California Public Employees Retirement System
Sacramento,
California
|
+$433M |
| 3 |
N
Nuveen
Charlotte,
North Carolina
|
+$197M |
| 4 |
Massachusetts Financial Services
Boston,
Massachusetts
|
+$158M |
| 5 |
APG Asset Management
Amsterdam,
Netherlands
|
+$124M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$918M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$312M |
| 3 |
Renaissance Technologies
New York
|
-$292M |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
-$241M |
| 5 |
Capital International Investors
Los Angeles,
California
|
-$216M |
VRTX Hedge Fund Activity: Q2 2020 in Review
964 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in Vertex Pharmaceuticals (VRTX) for Q2 2020, worth a combined $70.6B — up 21% from $58.4B a quarter earlier.
Buyers outnumbered sellers: 174 funds opened new VRTX positions and 59 closed out — a net gain of 115 holders — while 405 added to existing stakes and 271 trimmed.
The largest buyer was BlackRock, adding an estimated $863M. The largest seller was Fidelity Investments, cutting an estimated $918M.
- 964 institutional investors held Vertex Pharmaceuticals (VRTX) as of Q2 2020, up from 856 in Q1 2020.
- Funds reported $70.6B of Vertex Pharmaceuticals stock for Q2 2020, up 21% quarter-over-quarter.
- 174 funds opened new Vertex Pharmaceuticals positions in Q2 2020 and 59 closed out, a net change of +115 holders.
- The largest Vertex Pharmaceuticals buyer in Q2 2020 was BlackRock, an estimated $863M added.
- The largest Vertex Pharmaceuticals seller in Q2 2020 was Fidelity Investments, an estimated $918M sold.
Based on aggregated 13F filings for Q2 2020.